-
Emergency
-
Apollo Lifeline
-
Emergency
Morning Slots
AFTERNOON Slots
Dr Animesh Saha
Oncology
13+ Years Experience
MBBS, MD(Radiation Oncology), DNB(Radiation Oncology), MNAMS, PDCR, FRCR(London), CESR(UK), PGCME- Oncology (University of Dundee). Ex- Consultant Leeds Cancer Center, UK
Apollo Multispecialty Hospitals
English,Hindi,Bangla
Mon - Sun
12:00 -12:01
Dr Animesh Saha
Oncology
13+ Years Experience
MBBS, MD(Radiation Oncology), DNB(Radiation Oncology), MNAMS, PDCR, FRCR(London), CESR(UK), PGCME- Oncology (University of Dundee). Ex- Consultant Leeds Cancer Center, UK
Apollo Multispecialty Hospitals
English,Hindi,Bangla
Mon - Sun
12:00 -12:01
Description
Dr. Animesh Saha is a highly experienced Medical Oncologist based in Kolkata, West Bengal, with over 13 years of dedicated practice in the field of oncology. He holds an impressive array of qualifications, including FRCR (London), MD in Radiation Oncology, DNB in Radiation Oncology, CESR (UK), PGCME (Dundee), and MNAMS. He also completed his MBBS and is recognized as a PDCR professional. His extensive educational background equips him with the knowledge and expertise to deliver exceptional care to his patients.
Dr. Saha has previously served as a Consultant at the Leeds Cancer Centre in the UK, where he honed his skills in treating various types of cancer. His expertise extends to both common and rare oncological conditions, making him a valuable resource for patients seeking specialized care. He is committed to staying updated with the latest advancements in oncology, ensuring that his patients receive the best possible treatment options available.
Fluent in English, Hindi, and Bengali, Dr. Saha provides a comfortable communication environment for his diverse patient population, fostering a supportive and understanding space for discussing health concerns and treatment plans. His approach is patient-centered, emphasizing the importance of individualized care tailored to meet each patient's unique needs.
As an exclusive partner in the medical community, Dr. Animesh Saha continues to make a significant impact in the lives of those battling cancer, helping them navigate their journey with compassion and expertise. His dedication and commitment to his profession and patients have earned him respect and recognition in the field of Medical Oncology.
Experience
- Consultant Clinical Oncologist Apollo Gleneagles Hospitals, Kolkata from Nov 2019 Till now
- Consultant Clinical Oncologist Leeds Cancer Centre, UK, NHS trust from Nov 2018- Nov 2019
- Specialist registrar Leeds Cancer Centre, UK, NHS trust from March 2017 Nov 2018
- Clinical Oncology Fellow Tata Medical Center, Kolkata June 2013 to Jan 2017
- Post Graduate trainee IPGME&R and SSKM hospital, Kolkata June 2010 to June 2013
Special Interests
- Lung cancer, Mesothelioma, Thymoma, Head & neck cancer, GI cancers (Esophageal cancer, Stomach Cancer, Liver cancer, Gall bladder cancer, Pancreas cancer, Cholangiocarcinoma, Small bowel cancer, Colon Cancer, Rectal cancer, Anal canal cancer),Adult CNS tumor (Brain & Spine tumor).
- Urology cancer ( Bladder, Prostate, Kidney cancer).
Memberships
Certification
- Certificate of Eligibility for Specialist Registration (CESR), UK awarded by General Medical Council, UK in October 2019.
- Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
- FRCR in Clinical Oncology, Awarding body Royal College of Radiologists, April 2018.
- Professional diploma in clinical research awarded by Catalyst Clinical Services Pvt. Ltd, India, August,2014.
- DNB Radiotherapy awarded by National Board of Examinations, India in June,2014
- MD Radiotherapy awarded by The West Bengal University of Health Sciences in April 2014.
- M.B.B.S awarded by The West Bengal University of Health Sciences in November,2009
Professional Memberships
- Indian medical association (life member no- BGL/9348/119/305/161892/2011-12/L)
- Association of radiation oncologists of India ( life member no- 1672)
- European society of medical oncology (ESMO ID- 81560).
- Royal College of Radiologists (Membership no: 315972)
- European Society for Radiotherapy and Oncology (Membership no-24697)
- Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
Awards & Achievements
- Performed more than 20,000 Angiograms, 3,000 PTCA , 2,500 Coronary stentings, 75 cases of Percutaneous Trans Myocardial Laser Revascularization(PTMR), 500 Valvuloplasty, 200 cases of peripheral, renal, carotid Interventions including ASD and PDA closure, 12 cases of Drug eluting stent. Developed Mitral commissurotome along with Prof. Alain Cribier and performed first 7 cases of mitral dilatation in the world using Metallic Commissurotome Largest series of Balloon Mitral Valvuloplasty in the world using Bifoil balloon catheter (published in Journal of Cardiovascular diagnosis).
- First time performed Trans Radial Coronary Angioplasty and stenting in Asia Pacific region in ’94 ( Published in Indian Heart Journal also reported in the Limca book of world records). First time performed Venous graft intervention using protection device in India (published in Indian Heart Journal). Performed one of the highest number of Percutaneous Transluminal Myocardial Laser Revascularization (PTMR) in India (published in Indian Heart Journal). First time performed Carotid stenting by using protection device in India. (published in Indian Heart Journal) First time performed Drug Eluting stent in Asia Pacific region. Selected by the Cardiological Society of India and delivered DR K.K.DATEY MEMORIAL ORATION in the annual conference of Cardiological society of India at Kolkata on 06-12-03.
Research & Publication
Dr Saha has participated as a sub investigator in many international trials. Some of the trials are-
- A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
- Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers (ABC07 trial)
- A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases (CORE trial)
- ETOP/IFCT 4-12 STIMULI trial which is an Open-label, randomised, two-arm, phase II trial looking into addition of Immunotherapy with Nivolumab and Ipilumumab to standard of care in limited stage Small cell lung carcinoma.
- A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
- GO40241 Phase III randomized, double-blind, placebo-controlled study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
- Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer: A randomised phase III trial (SARON study)
- A multi-centre randomised study of induction chemotherapy followed by capecitabine(+/-nelfinavir) with high or standard dose radiotherapy for locally advanced nonmetastatic pancreatic cancer (SCALOP 2 study)
- A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma. (SYSTEM 2 trial).
- A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
- A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006).
- Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study).
- Adjuvant Durvalumab following sequential chemotherapy and radiotherapy in patients with unresecatble stage III NSCLC (PACIFIC 6 study).
Dr Saha has numerous publications in national and international peer reviewed journals. Some of his publications include-
- Can Dosimetry Affect Overall Survival in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer Treated with Stereotactic Ablative Radiotherapy (SABR)? An Analysis of 1300 Patients.
- Setting up a lung Stereotactic Body Radiotherapy (SBRT) service in a tertiary centre in eastern India– The process, quality assurance and early experience.
- Radical radiotherapy or chemoradiotherapy for inoperable locally advanced non-small-cell lung cancer (NSCLC) - Analysis of patient profile, treatment approaches and outcomes of 213 patients at a tertiary cancer centre.
- A Prospective Study of an Offline Matching Protocol for Head and Neck Cancer on Helical Tomotherapy: The F5 Study.
- Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study.
- High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
- Quality Assurance and Acute Toxicities of a 2 Week Hypofractionated Palliative Radiotherapy Schedule used in a Prospective Phase I/II Study (HYPORT Study).
- Evaluating the Need for Daily Image Guidance in Head and Neck Cancers Treated with Helical Tomotherapy: A Retrospective Analysis of Large Number of Daily Imaging-based Corrections. Clin Oncol, 2016.
- Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
- Helical tomotherapy based intensity modulated radiotherapy for the management of difficult clinical situations in breast cancer.
- A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
